Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of adult onset Rheumatoid Arthritis (RA) in line with the protocol~* Moderately active disease in line with the protocol~* A pre-defined number of swollen joints in line with the protocol~* Inadequate response to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs)~* No evidence of respiratory disease.~Exclusion Criteria:~* A rheumatic autoimmune disease other than RA, or significant systemic extra-articular involvement secondary to RA~* A history of, or current, inflammatory joint disease other than RA~* Previous treatment with the investigational drug~* Discontinuation of a biologic DMARD due to lack of efficacy~* Non-compliant concurrent medications~* Non-compliance with medical history criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 milligram \[mg\] per week) through oral or parenteral route.
- Mavrilimumab 30 mg (Type: EXPERIMENTAL): Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
- Mavrilimumab 100 mg (Type: EXPERIMENTAL): Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
- Mavrilimumab 150 mg (Type: EXPERIMENTAL): Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.

Based on this trial design, predict the completion outcome and termination type (if applicable).